Complex conjugate

Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development

Retrieved on: 
Tuesday, February 27, 2024

The collaboration aims to leverage Nona's proprietary Harbour Mice® H2L2 (two light and two heavy chain) platform to accelerate the development of Antibody-Drug Conjugates (ADCs) against novel targets.

Key Points: 
  • The collaboration aims to leverage Nona's proprietary Harbour Mice® H2L2 (two light and two heavy chain) platform to accelerate the development of Antibody-Drug Conjugates (ADCs) against novel targets.
  • Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, expressed, "By leveraging our accumulated knowledge of ADC discovery and utilizing our advanced therapeutic antibody platforms validated by partners worldwide, this collaboration will expedite the development of first-in-class ADCs targeting cancer.
  • Gwanghee Lee, Founder and CEO of Boostimmune, stated, "We are excited to collaborate with Nona Biosciences.
  • Through this collaboration, we are confident in making significant strides in addressing the unmet needs of cancer patients."

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Retrieved on: 
Thursday, January 4, 2024

DOYLESTOWN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting recent developments and plans for advancement of its pipeline of DNA Damage Response (DDR) anti-cancer agents in 2024.

Key Points: 
  • DOYLESTOWN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting recent developments and plans for advancement of its pipeline of DNA Damage Response (DDR) anti-cancer agents in 2024.
  • The most recent analysis of the data cut (January 2, 2024) shows that two patients have achieved stable disease – one each in the 50 mg and 200 mg cohorts.
  • Upon the addition of the higher dose cohorts, Aprea expects to determine the recommended Phase 2 dose (RP2D) in the second half of 2024.
  • Aprea will be hosting institutional investor and business development meetings at the Annual Corporate Access Event in San Francisco, hosted by our investor relations firm LifeSci Partners.

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset

Retrieved on: 
Wednesday, December 20, 2023

“We are excited with our findings of unprecedented survival and clinical benefit in very difficult-to-treat patients who failed ADCs and view our findings as a significant clinical breakthrough in the field of cancer therapy.

Key Points: 
  • “We are excited with our findings of unprecedented survival and clinical benefit in very difficult-to-treat patients who failed ADCs and view our findings as a significant clinical breakthrough in the field of cancer therapy.
  • Kaplan-Meier analysis showed median overall survival (OS) that was up to twice that reported in the literature, with some patients recording survival of over a year.
  • Progression free survival (PFS) was similar or better than that of the patients’ prior therapy in 40% of patients, highlighting clinical benefit and tolerability of the Bria-IMT™ regimen.
  • 17 of 23 patients remain alive as of today, suggesting efficacy, tolerability, and survival benefit of BriaCell’s Bria-IMT™ regimen.

Global High Potency Active Pharmaceutical Ingredients Market to 2030: Growth of Targeted Therapies Fuels the Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 15, 2023

The growth of the HPAPI market is attributed to rising incidence of cancer, growing targeted therapies, and increasing application of high potency active pharmaceutical ingredients (HPAPI) in treating target diseases.

Key Points: 
  • The growth of the HPAPI market is attributed to rising incidence of cancer, growing targeted therapies, and increasing application of high potency active pharmaceutical ingredients (HPAPI) in treating target diseases.
  • According to the WHO, cancer is the second leading cause of death, accounting for around 9.9 million deaths in 2020.
  • Due to the growing number of people who contract the disease, cancer is regarded as one of the major health risks.
  • The expansion was aimed at capacity enhancement of its small scale facilities for CGMP production of high potency APIs.

Lung Cancer Therapies Market to Amplify Significantly over 2022-2029 - Brandessence Market Research

Retrieved on: 
Monday, May 29, 2023

With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.

Key Points: 
  • With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.
  • The business intelligence report on Lung Cancer Therapies Market by Brandessence Market Research is curated with an aim to provide the industry participants with a succulent overview of this industry.
  • By treatment, the chemotherapy segment is projected to amass notable gains due to its efficacy in treating lung cancer.
  • The Lung Cancer Therapies Market is anticipated to garner significant returns over the estimated timeline of 2022-2029.

High Potency Active Pharmaceutical Ingredients Global Market Report 2023: Growth of Targeted Therapies and Rising Prevalence of Cancer Drives Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, March 31, 2023

The "High Potency Active Pharmaceutical Ingredients Market, by Product, by Manufacturer, by Drug, by Application, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "High Potency Active Pharmaceutical Ingredients Market, by Product, by Manufacturer, by Drug, by Application, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • Growing applications of HPAPI, growth of targeted therapies, and an increase in the incidence of cancer are some of the factors contributing to the market growth.
  • Rising investment in manufacturing facilities are expected to fuel the market growth during the forecast period.
  • The high potency active pharmaceutical ingredients market involves complicated materials with significant production and manufacturing unit establishment costs.

BIG IMPACT, SMALL PACKAGE: DEBIOPHARM LAUNCHES A WAZOKU OPEN-INNOVATION CHALLENGE FOR SMALL ANTIBODY DRUG CONJUGATE TECHNOLOGY

Retrieved on: 
Thursday, September 22, 2022

Through Wazoku, an open innovation crowdsourcing platform, the Challenge has been launched globally to participants from various backgrounds, including science, engineering, and technology.

Key Points: 
  • Through Wazoku, an open innovation crowdsourcing platform, the Challenge has been launched globally to participants from various backgrounds, including science, engineering, and technology.
  • This challenge will require the submission of a written proposal directly via the Wazoku Platform before October 15th, 2022.
  • ADCs are large and complex molecules composed of an antibody, with two Fab and a Fc, linked to a biologically active cytotoxic payload.
  • Through this Challenge, Debiopharm hopes to develop new non-invasive diagnostic methods and to improve the specificity of Drug Targeting to best preserve healthy tissue.

BIG IMPACT, SMALL PACKAGE: DEBIOPHARM LAUNCHES A WAZOKU OPEN-INNOVATION CHALLENGE FOR SMALL ANTIBODY DRUG CONJUGATE TECHNOLOGY

Retrieved on: 
Thursday, September 22, 2022

Through Wazoku, an open innovation crowdsourcing platform, the Challenge has been launched globally to participants from various backgrounds, including science, engineering, and technology.

Key Points: 
  • Through Wazoku, an open innovation crowdsourcing platform, the Challenge has been launched globally to participants from various backgrounds, including science, engineering, and technology.
  • This challenge will require the submission of a written proposal directly via the Wazoku Platform before October 15th, 2022.
  • ADCs are large and complex molecules composed of an antibody, with two Fab and a Fc, linked to a biologically active cytotoxic payload.
  • Through this Challenge, Debiopharm hopes to develop new non-invasive diagnostic methods and to improve the specificity of Drug Targeting to best preserve healthy tissue.

Merck KGaA, Darmstadt, Germany Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor

Retrieved on: 
Wednesday, September 21, 2022

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l.

Key Points: 
  • Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l.
  • (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) polymerase) inhibitor, NMS-293.
  • Under the current agreement, Merck KGaA, Darmstadt, Germany will make early payments (up-front and option exercise fees) of up to $65 million to NMS.
  • Upon exercise of the option, NMS will grant to Merck KGaA, Darmstadt, Germany the exclusive rights to research, develop, manufacture, and commercialize NMS-293.

Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor

Retrieved on: 
Wednesday, September 21, 2022

Merck, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l.

Key Points: 
  • Merck, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l.
  • (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) polymerase) inhibitor, NMS-293.
  • Under the current agreement, Merck will make early payments (up-front and option exercise fees) of up to $65 million to NMS.
  • Upon exercise of the option, NMS will grant to Merck the exclusive rights to research, develop, manufacture, and commercialize NMS-293.